News
News
- FDA Grants Catalyst Biosciences Orphan Drug Designation for MarzAA for the Treatment of Factor VII Deficiency
09/28/2021 / 22:01 - GlobeNewswire - Catalyst Biosciences to Present at the Cantor Global Healthcare Conference
09/24/2021 / 14:00 - GlobeNewswire - SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cassava Sciences, Inc. - SAVA
09/24/2021 / 02:54 - GlobeNewswire - Dow opens more than 200 pts higher after Fed calls
09/23/2021 / 15:31 - TeleTrader - Biogen R&D Day to Provide Overview of Diversified Pipeline and Capabilities with Potential for Multiple Novel Therapies in Neuroscience
09/21/2021 / 14:30 - GlobeNewswire - FDA Approves Samsung Bioepis and Biogen’s BYOOVIZ™ (SB11), LUCENTIS® Biosimilar (ranibizumab-nuna)
09/20/2021 / 13:30 - GlobeNewswire - FDA Approves Samsung Bioepis and Biogen’s BYOOVIZ™ (SB11), LUCENTIS® Biosimilar (ranibizumab-nuna)
09/20/2021 / 13:30 - GlobeNewswire - CHMP Recommends VUMERITY® (diroximel fumarate) for Approval in the European Union as a Treatment for Relapsing-Remitting Multiple Sclerosis
09/17/2021 / 15:09 - GlobeNewswire - Biogen Announces Positive Topline Results from Phase 2 CONVEY Study in Small Fiber Neuropathy
09/16/2021 / 13:30 - GlobeNewswire - Jounce Therapeutics Appoints Jigar Raythatha to its Board of Directors
09/15/2021 / 14:00 - GlobeNewswire
Real-time